Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCerillion Regulatory News (CER)

Share Price Information for Cerillion (CER)

Share Price is delayed by 15 minutes
Get Live Data
1,245.00    0.00 (0.00%)
Bid:
1,220.00
Ask:
1,270.00
Spread: 50.00 (4.098%)
Market Cap: £367.78m
CER Live PriceLast checked at - London Stock Exchange

Intraday Cerillion Share Chart

Further concentrate purchase

1 Oct 2007 07:02

Celtic Resources Holdings PLC01 October 2007 1 October 2007 Celtic Resources Holdings Plc ("Celtic" or the "Company") Celtic enters into agreement to purchase concentrates Celtic is pleased to announce that it has entered into an agreement with asubsidiary of European Goldfields Limited, Hellas Gold S.A. ("Hellas Gold"), forthe purchase of 50,000 tonnes of concentrates containing approximately 30,000 ozof gold. As announced on 22 September 2006, the Company acquired 9,000 tonnes ofconcentrate containing approximately 6,000 oz of gold, to be processed on atrial basis, by Celtic at its Suzdal BIOX(R) plant in Kazakhstan. The Companyalso announced that, if the initial shipments proved successful, it intended topurchase up to an additional 120,000 tonnes of concentrates from Hellas Gold.The Company has been very satisfied by the results of the trial and is thereforeannouncing an agreement to purchase a further 50,000 tonnes of concentrates,with shipments expected to be completed by the end of September 2009. The Company operates the only BIOX(R) plant in the FSU for the treatment ofrefractory sulphide ores and in addition to treating ore produced at its Suzdalmine, it will be utilising available BIOX(R) capacity to produce more gold. Suzdal has produced over 28,599 oz of gold in the last three months, whichincludes 11,780 oz produced in September, at an average sale price of US$718 peroz. Kevin Foo, Managing Director of Celtic, said, "We have been delighted with theresults of our initial trial to process third party concentrates at our SuzdalBIOX(R) plant. This agreement is a significant step forward in our strategy tocapitalise on our technology advantages at Suzdal and we are also looking atother third party concentrate opportunities within Kazakhstan and Russia, asmany refractory gold ores remain unexploited." Contact information: Kevin Foo / Jonathan Scott-BarrettCeltic Resources Holdings PlcTel: + 44 (0)20 7921 8800Investors@celtic resources.com Leesa Peters / Jane StaceyConduit PRTel: +44 (0)20 7429 6606 / (0)792 292 3306leesa@conduitpr.com Anthony CardewCardew GroupTel: +44 (0)20 7930 0777anthony.cardew@cardewgroup.com Strand Partners LimitedSimon RaggettStuart FaulknerTel: +44 (0)20 7409 3494 About the Suzdal BIOX(R) plant: Celtic has successfully developed the first BIOX(R) plant for treatment ofrefractory sulphide ores in the FSU at its Suzdal mine in Kazakhstan. The plantuses a sulphide oxidation process for recovering gold from refractory ores orconcentrates. The process utilises a mixed population of naturally occurringbacteria, that are present in all sulphide ores, to break down the sulphidemineral matrix, thereby liberating the occluded gold for subsequent cyanidation. The BIOX(R) process acts as an alternative to conventional processes of roastingand pressure oxidation and offers advantages of reduced capital cost, simplicityof operations, robustness and very low environmental impact. Any person who is the holder of 1 per cent. or more of any class of shares inCeltic may be required to make disclosures pursuant to Rule 8.3 of the IrishTakeover Panel Act, 1997, Takeover Rules 2001 to 2006. The Directors of Celtic accept responsibility for the information contained inthis announcement and to the best of their knowledge and belief (having takenall reasonable care to ensure that such is the case), the information containedin this announcement is in accordance with the facts and, where appropriate,does not omit anything likely to affect the import of such information. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
30th Nov 20226:29 pmRNSPDMR and PCA shareholding
30th Nov 202211:18 amRNSHolding(s) in Company
28th Nov 20227:00 amRNSFinal Results
23rd Nov 20227:00 amRNSNotice of Results and Investor Presentation
2nd Nov 20225:49 pmRNSHolding(s) in Company
2nd Nov 202212:40 pmRNSHolding(s) in Company
26th Oct 20227:00 amRNSRelease of latest version of flagship product set
24th Oct 20227:00 amRNSTrading Update
6th Oct 20227:00 amRNSAppointment of Joint Broker
25th Aug 20223:48 pmRNSGrant of Options
8th Aug 20223:08 pmRNSHolding(s) in Company
28th Jul 20224:35 pmRNSPrice Monitoring Extension
19th Jul 20227:00 amRNSHolding(s) in Company
6th Jul 20227:00 amRNSMajor Contract Win
13th May 20227:33 amRNSDirector Share Purchase
9th May 20227:00 amRNSInterim Results Presentation
9th May 20227:00 amRNSInterim Results
25th Apr 202210:13 amRNSHolding(s) in Company
19th Apr 20227:00 amRNSH1 2022 Trading Update
6th Apr 20227:00 amRNSCerillion Client MVN-X Reaches Million Subscribers
7th Mar 20227:00 amRNSWins Prestigious Megabuyte Performance Award
2nd Mar 20227:00 amRNSExercise of Options, PDMR Shareholding & TVR
21st Feb 20223:08 pmRNSHolding(s) in Company
21st Feb 20227:00 amRNSShare purchase for Employee Share Option Scheme
15th Feb 20227:00 amRNSRecognised in Two Gartner Market Guide Reports
4th Feb 202211:37 amRNSResult of AGM
31st Jan 20227:00 amRNSConfirmation of Board Appointment
27th Jan 20222:25 pmRNSHolding(s) in Company
24th Jan 20222:05 pmRNSSecond Price Monitoring Extn
24th Jan 20222:00 pmRNSPrice Monitoring Extension
10th Jan 20227:00 amRNSCompletion of Implementation for Norlys
14th Dec 20217:00 amRNSBoard Retirement and Proposed Appointment
26th Nov 20218:37 amRNSPDMR and PCA Shareholding
22nd Nov 20217:00 amRNSFinal Results
16th Nov 20212:42 pmRNSHolding(s) in Company
2nd Nov 20217:00 amRNSRelease of Cerillion 21.2
4th Oct 20217:02 amRNSTrading Update
28th Sep 20217:00 amRNSContracts worth £4.2m with OpenNet
23rd Sep 20216:15 pmRNSHolding(s) in Company
9th Sep 20217:00 amRNSOpening of Bulgaria office
8th Sep 20217:00 amRNSInvestor Presentation
22nd Jul 20214:24 pmRNSHolding(s) in Company
13th Jul 202111:03 amRNSHolding(s) in Company
6th Jul 202111:30 amRNSDirector/PDMR Shareholding
22nd Jun 20217:00 amRNSGrant of Options
18th Jun 20217:00 amRNSEmployee Share Option Scheme
10th Jun 202111:35 amRNSDirector/PDMR shareholding
27th May 20216:03 pmRNSReplacement: Director/PDMR Shareholding
27th May 20213:50 pmRNSDirector/PDMR Shareholding
24th May 20214:59 pmRNSExercise of Options and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.